New research reveals that patients who stop using blockbuster slimming jabs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who end traditional lifestyle regimens.
Published data in a major health publication demonstrates that while obese individuals often shed substantial amounts of their body weight while using the jabs, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"Individuals buying these treatments must be informed of the risk of fast rebound weight gain when the therapy ends," cautioned expert Dr. Susan Jebb.
That rate of regain suggests a reversion to pre-treatment mass in about a year and a half.
Weighing Treatments
The analysis, which looked at dozens of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with older methods.
The team note that individuals who shed pounds through dieting generally see a more gradual weight regain—around 100 grams monthly—after stopping.
Understanding the Fast Regain
Nutrition scientists suggest the way of the jabs accounts for the accelerated rebound.
These medications copy a natural hormone called GLP-1, which moderates hunger.
"Sustained high doses of GLP-1 levels several times higher than normal might result in the body to produce less of its endogenous GLP-1, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication leads to hunger is unsuppressed, making excessive eating far more likely."
A Lifelong Issue?
Health authorities suggest the jabs for individuals with weight-linked medical conditions, alongside prescribed lifestyle changes.
A number of clinicians say that, due to the high risk of weight regain, the treatment is often life-long.
This perspective is reinforced by pharmaceutical companies, who say that the results "underscore the chronic nature of obesity," similar to managing conditions like high blood pressure.
Patient Accounts
People who have stopped the medication describe a intense resurgence of cravings.
"It felt as if a switch activating and you become extremely hungry," said an individual.
This difficulty is worsened if individuals have not established permanent lifestyle or habit changes during treatment.
Growing Interest
Recent estimates show that millions of adults in the UK have tried these injections in the past year, with demand being substantial.
- Adoption is higher among women than men.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic solution and lasting health benefits relies on ongoing behavioural management.
